CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Guangdong Hybribio Biotech Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Guangdong Hybribio Biotech Co Ltd
Community D5-3-3-4, North High-Tech Zone
Economic Development Zone Pilot Area
Phone: +86 7682852923p:+86 7682852923 CHAOZHOU, GNG  521000  China Ticker: 300639300639
Business Summary
Guangdong Hybribio Biotech Co Ltd is a company mainly engaged in production and sales of vitro diagnostic reagents. The Company operates two segments. The In Vitro Diagnostic Reagents and Supporting Equipment segment operates the research, development and production of nucleic acid detection reagents and supporting equipment, such as cervical cancer detection series products, deafness susceptibility gene detection series products and reproductive health management series products. The products are used in hospital clinical testing, large-scale population screening and other areas. The Medical Testing Service segment is involved in providing medical testing services for medical institutions, and the testing programs cover genetic metabolic diseases, infectious diseases, molecular pathological testing and tumor examinations.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022Yes----

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board QiaozhongGuan 72 9/1/2022
Vice Chairman of the Board WeixiongHuang 59 9/1/2022
Chief Financial Officer QinghuiLi 56
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3,339 (As of 12/31/2022)
Outstanding Shares: 646,500,674 (As of 2/29/2024)
Shareholders: 41,611
Stock Exchange: SHE
Fax Number: +86 7682852920


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024